Sinovac Biotech Ltd. (SVA)
Price:
6.47 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
NEWS
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
businesswire.com
2025-07-11 16:21:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the “Special Meeting”): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity (“PIPE”) to.
Newly Elected Directors of Sinovac Hold the First Board Meeting
businesswire.com
2025-07-10 07:23:00BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquarters in Beijing.
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
businesswire.com
2025-07-09 12:34:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, categorically rejects the recent deceptive and illegal claims by SAIF and the Imposter Former Board that it purported to “reconvene” the adjourned Special Meeting of Shareholders (the “Special Meeting”) and announced sham voting results of the shareholder proposals. At the July 8, 2025 Special Meeting, SINOVAC Chairman Chiang Li valid.
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
businesswire.com
2025-07-09 12:27:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of the close of business on July 7, 2025. On July 8, 2025, the Paying Agent and the Transfer Agent confirmed valid SINOVAC shareholders. Those share.
SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares
businesswire.com
2025-07-09 01:39:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Special Meeting of Shareholders (the “Special Meeting”) held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time) has been adjourned, pending resolution of litigation in Antigua related to the validity of shares issued following an.
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
businesswire.com
2025-07-09 01:05:00PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction sought and led by 1Globe to prevent legitimate, long-term shareholders in the Company from participating in its cri.
Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2
businesswire.com
2025-07-07 15:26:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent shareholders a final reminder to vote ahead of the Company's Special Meeting of Shareholders (the “Special Meeting”) on Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time (Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time). Valid shareholders are urged to follow the recommendations of leading inde.
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
businesswire.com
2025-07-07 01:46:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC (“1Globe”) for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, “relief relating to governance outcomes o.
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
businesswire.com
2025-07-03 19:34:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has joined Glass, Lewis & Co. (“Glass Lewis”) in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted.
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
businesswire.com
2025-07-02 11:39:00NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT.
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
businesswire.com
2025-07-02 10:55:00PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo's motion for a preliminary injunction against 1Globe Capital, LLC and its owner Jiaqiang “Chiang” Li (collectively, “1Globe”), barring 1Globe from making.
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
businesswire.com
2025-07-02 09:20:00NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the “Board”) using the GOLD proxy card. Sinovac's Special Meeting of Shareholders (the “S.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place
businesswire.com
2025-07-02 01:03:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that SINOVAC shareholders vote to keep the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meetin.
SAIF Partners Sends Letter to Sinovac Shareholders
businesswire.com
2025-07-01 15:02:00NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board's empty promises to shareholders, numerous failures overseeing the Company, and certain directors' concerning patterns of reckless, unethical and illegal actions to retain control of Sinovac. The full tex.
SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card “AGAINST” the Misguided Proposals to Remove SINOVAC's Current Board
businesswire.com
2025-06-30 06:30:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent a letter to shareholders ahead of the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). The full text of the letter follows: Dear SINOVAC Shareholder, It is time to act. Your vote at the upcoming Sp.
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
businesswire.com
2025-06-27 19:12:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success (“Advantech/Prime”) in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief so.
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
businesswire.com
2025-07-11 16:21:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the “Special Meeting”): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity (“PIPE”) to.
Newly Elected Directors of Sinovac Hold the First Board Meeting
businesswire.com
2025-07-10 07:23:00BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquarters in Beijing.
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
businesswire.com
2025-07-09 12:34:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, categorically rejects the recent deceptive and illegal claims by SAIF and the Imposter Former Board that it purported to “reconvene” the adjourned Special Meeting of Shareholders (the “Special Meeting”) and announced sham voting results of the shareholder proposals. At the July 8, 2025 Special Meeting, SINOVAC Chairman Chiang Li valid.
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
businesswire.com
2025-07-09 12:27:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of the close of business on July 7, 2025. On July 8, 2025, the Paying Agent and the Transfer Agent confirmed valid SINOVAC shareholders. Those share.
SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares
businesswire.com
2025-07-09 01:39:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Special Meeting of Shareholders (the “Special Meeting”) held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time) has been adjourned, pending resolution of litigation in Antigua related to the validity of shares issued following an.
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
businesswire.com
2025-07-09 01:05:00PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the Court of Appeals of the Eastern Caribbean Supreme Court granted a motion to stay the self-interested injunction sought and led by 1Globe to prevent legitimate, long-term shareholders in the Company from participating in its cri.
Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2
businesswire.com
2025-07-07 15:26:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent shareholders a final reminder to vote ahead of the Company's Special Meeting of Shareholders (the “Special Meeting”) on Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time (Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time). Valid shareholders are urged to follow the recommendations of leading inde.
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
businesswire.com
2025-07-07 01:46:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC (“1Globe”) for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, “relief relating to governance outcomes o.
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
businesswire.com
2025-07-03 19:34:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has joined Glass, Lewis & Co. (“Glass Lewis”) in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted.
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
businesswire.com
2025-07-02 11:39:00NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT.
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
businesswire.com
2025-07-02 10:55:00PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today announced that the United States District Court of Massachusetts (“the Court”) granted Vivo's motion for a preliminary injunction against 1Globe Capital, LLC and its owner Jiaqiang “Chiang” Li (collectively, “1Globe”), barring 1Globe from making.
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
businesswire.com
2025-07-02 09:20:00NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote “FOR” the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the “Board”) using the GOLD proxy card. Sinovac's Special Meeting of Shareholders (the “S.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place
businesswire.com
2025-07-02 01:03:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that SINOVAC shareholders vote to keep the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meetin.
SAIF Partners Sends Letter to Sinovac Shareholders
businesswire.com
2025-07-01 15:02:00NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, today sent a letter to Sinovac shareholders regarding the current Board's empty promises to shareholders, numerous failures overseeing the Company, and certain directors' concerning patterns of reckless, unethical and illegal actions to retain control of Sinovac. The full tex.
SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card “AGAINST” the Misguided Proposals to Remove SINOVAC's Current Board
businesswire.com
2025-06-30 06:30:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent a letter to shareholders ahead of the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). The full text of the letter follows: Dear SINOVAC Shareholder, It is time to act. Your vote at the upcoming Sp.
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
businesswire.com
2025-06-27 19:12:00BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success (“Advantech/Prime”) in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief so.